Oribiotech - About the company
Oribiotech is a series B company based in London (United Kingdom), founded in 2015 by Chris Mason and Farlan Veraitch. It operates as a Biotech company focused on advancing cell and gene therapy manufacturing through innovative automation tool. Oribiotech has raised $143M in funding from investors like Amadeus Capital, Octopus Ventures and Kindred Capital, with a current valuation of £*****. The company has 32 active competitors, including 10 funded and 2 that have exited. Its top competitors include companies like Multiply Labs, Cellares and Cellular Origins.
Company Details
Biotech company focused on advancing cell and gene therapy manufacturing through innovative automation tool. The technology integrates bioreactor systems and sterile connection tools to facilitate the manufacturing of biological products. The equipment supports process control and scalability throughout the development cycle, from research stages to commercial production. The system design aims to improve reproducibility and throughput in the creation of therapeutic materials.
- Website
- oribiotech.com
- Social
- Email ID
- *****@oribiotech.com
Key Metrics
Founded Year
2015
Location
London, United Kingdom
Stage
Series B
Total Funding
$143M in 5 rounds
Latest Funding Round
Post Money Valuation
£***** as on Jun 22, 2022
Investors
Ranked
2nd among 32 active competitors
Annual Revenue
£1M - £10M as on Dec 31, 2025
Employee Count
68 as on Sep 30, 2026
Similar Companies
Legal entities associated with Oribiotech
Oribiotech is associated with 1 legal entity given below:
Legal Entity Name | Date of Incorporation | Revenue | Latest Employee Count | Reports |
|---|---|---|---|---|
Oribiotech Ltd CIN: 9757696 , United Kingdom, Active | Sep 01, 2015 | £1M - £10M (As on Dec 31, 2025) | 52 (As on Dec 31, 2024) |
Sign up to download Oribiotech's company profile
Oribiotech's funding and investors
Oribiotech has raised a total funding of $143M over 5 rounds. Its first funding round was on Nov 09, 2016. Its latest funding round was a Series B round on Jan 05, 2022 for $*****. 7 investors participated in its latest round. Oribiotech has 10 institutional investors and 9 angel investors.
Here is the list of recent funding rounds of Oribiotech:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jan 05, 2022 | 4341667 | Series B | 1101858 | 8878196 | 1943948 | 3729576 |
Sep 07, 2020 | 8368979 | Series A | 5791007 | 3372537 | 4438110 | |
Aug 20, 2019 | 2614327 | Seed | 4012160 | 6061894 | 1821964 |
Access funding benchmarks and valuations. Sign up today!View details of Oribiotech's funding rounds and investors
Oribiotech's founders and board of directors
Founder? Claim ProfileThe founders of Oribiotech are Chris Mason and Farlan Veraitch. Jason C Foster is the CEO of Oribiotech.
Here are the details of Oribiotech's key team members:
- Chris Mason: Former Co-Founder of Oribiotech and founder of 1 other company. They serve on the board of 1 company.
- Farlan Veraitch: Co-Founder & Chief Scientific Officer of Oribiotech. They serve on the board of 1 company.Contact Info: 1 email address
- Jason C Foster: CEO of Oribiotech. They are also an angel investor in 1 startup and serve on the board of 1 company.Contact Info: 1 email address
Oribiotech's Board of Directors
Oribiotech's board has 10 active members. Chris Mason, Farlan Veraitch and Jason C Foster are part of team and Pierre Robert Socha, Jonathan Russell Hay, Annalisa Mary Jenkins, Barry Clare, Paul Matthew Meister, Andrea Liapis Jackson and Adam Joseph Wieschhaus are independent board members.Here is the list of Oribiotech's board of directors:
Name | Type | Representing | Status | Duration |
|---|---|---|---|---|
Team | - | Current | 11y 0m | |
Team | - | Current | 7y 1m | |
svvgxju | Team | - | Past | 5y 1m |
grbntni | Investor | - | Past | 7y 3m |
Independent board member | - | Current | 7y 1m | |
wfzyd{v | Independent board member | - | Current | 2y 7m |
sssvf{w | Independent board member | - | Current | 3y 7m |
d{ajnrc | Independent board member | - | Current | 7y 2m |
zedkufd | Independent board member | - | Current | 9y 3m |
wdmzync | Independent board member | - | Current | 9y 5m |
wtlckwm | Independent board member | - | Current | 4y 7m |
cwbkyca | Independent board member | - | Past | 1y 8m |
jfwwzga | Independent board member | - | Past | 7y 1m |
View details of Oribiotech's Founder profiles and Board Members
Oribiotech's employee count trend
Oribiotech has 68 employees as of Sep 26. Here is Oribiotech's employee count trend over the years:
Uncover Oribiotech's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Oribiotech's Competitors and alternates
Top competitors of Oribiotech include Multiply Labs, Cellares and Cellular Origins. Here is the list of Top 10 competitors of Oribiotech, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Multiply Labs 2016, San Francisco (United States), Series A | Manufacturer of precision medicines through innovative robotic technology | $41.3M | 69/100 | |
2nd | Oribiotech 2015, London (United Kingdom), Series B | Biotech company focused on advancing cell and gene therapy manufacturing through innovative automation tool | $143M | 63/100 | |
3rd |  Cellares 2019, San Francisco (United States), Series D | Manufacturer of a medical device for cell-based therapy | $682M | 64/100 | |
4th |  Cellular Origins 2022, Melbourn (United Kingdom), Series A | Provider of automated manufacturing solution for cell and gene therapy | $40M | 55/100 | |
5th | Provider of a device for autologous cell and gene therapies | $18M | 55/100 | ||
6th |  Unicorn Biotechnologies 2020, Sheffield (United Kingdom), Seed | Developer of bioreactors for cell-based manufacturing | $3.45M | 44/100 | |
7th |  Shenzhen Shenyan Biotechnology 2014, Shenzhen (China), Series B | Developer of automated cell processing system | $56.7M | 40/100 | |
8th | ThermoGenesis 1986, Rancho Cordova (United States), Public | Provider of automated technologies for cell-based therapeutics and bio-processing | - | 40/100 | |
9th |  Celltrio 2018, Fremont (United States), Series B | Developer of automated biobanking and cell culture systems | $15M | 39/100 | |
10th |  Cell X Technologies 2017, Cleveland (United States), Funding Raised | Developer of regenerative medicine to measure and manage human cell sources | - | 35/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Oribiotech's competitors? Click here to see the top ones
Oribiotech's Investments and acquisitions
Oribiotech has made no investments or acquisitions yet.
Reports related to Oribiotech
Here is the latest report on Oribiotech's sector:
News related to Oribiotech
Filter this listMedia has covered Oribiotech for a total of 5 events in the last 1 year, 3 of them have been about company updates and 1 about partnerships.
•
Ori Biotech Secures 10-Year, $120M Deal for Commercial Cell Therapy ManufacturingContract Pharma•Sep 16, 2026•Oribiotech
•
Amid industry’s cell therapy automation push, Cellares and Ori dominate the fieldFiercepharma•Jun 18, 2026•Oribiotech
•
Ori Biotech and ImmuXell Announce Strategic Partnership and Dose First PatientBusiness Wire•May 27, 2026•Shanghai Bintie Biotechnology, Oribiotech
•
Oribiotech, Cell Therapies and AdAlta join forces to tackle cell therapy manufacturing challenges.Oribiotech•Apr 21, 2026•Adalta, Oribiotech, Cell Therapies
•
•
As Ori Wins Designation, FDA’s Advanced Manufacturing Program Nears Proof PointBioSpace•Sep 09, 2025•Oribiotech
•
Ori-Biotech’s IRO® Platform Receives FDA Advanced Manufacturing Technology (AMT) DesignationBusiness Wire•Sep 03, 2025•Oribiotech
•
MaxCyte and Ori Biotech Collaborate to Improve Manufacturing EfficienciesGlobeNewswire•Jun 11, 2025•MaxCyte, Oribiotech
•
MaxCyte and Ori Biotech Partner to Improve Cell Therapy Manufacturing EfficiencyMorningstar•Jun 11, 2025•MaxCyte, Oribiotech
•
MaxCyte and Ori Biotech collaborate to enhance cell therapy manufacturingShareprices•Jun 11, 2025•MaxCyte, Oribiotech
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Oribiotech
Explore our recently published companies
- BUBBA'S TIRE CENTER - Georgia based, Unfunded company
- GTA Wildlife Removal - 1994 founded, Unfunded company
- Stage AI - Unfunded company
- Chromaprinting - Pleasanton based, 1984 founded, Unfunded company
- SILVER CREEK AUTO BODY - Silverton based, 1994 founded, Unfunded company
- Smart Roar - Los Angeles based, Unfunded company
